Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Ravindra Mylavagnanam"'
Autor:
Ravindra Mylavagnanam, Sridhar Ramaswamy, Elena Zarcaro, Srinivas Vinod Saladi, Andrea Desmond, Murat Yildirim, Varunika Vivekanandan, Michael S. Lawrence, Kenneth N. Ross, Mihriban Karaayvaz-Yildirim, Rebecca E. Silberman, Adam Langenbucher, Leif W. Ellisen, Angelika Amon, Michelle C. Specht, Hiranmayi Ravichandran
Publikováno v:
Science Advances. 6
Women harboring heterozygous germline mutations of BRCA2 have a 50 to 80% risk of developing breast cancer, yet the pathogenesis of these cancers is poorly understood. To reveal early steps in BRCA2-associated carcinogenesis, we analyzed sorted cell
Autor:
Michelle C. Specht, Murat Yildirim, Michael S. Lawrence, Mihriban Karaayvaz, Srinivas Vinod Saladi, Angelika Amon, Adam Langenbucher, Rebecca E. Silberman, Varunika Vivekanandan, Andrea Desmond, Leif W. Ellisen, Sridhar Ramaswamy, Kenneth N. Ross, Ravindra Mylavagnanam, Elena Zarcaro, Hiranmayi Ravichandran
Women harboring heterozygous germline mutations of BRCA2 have a 50-80% risk of developing breast cancer, yet the early pathogenesis of these cancers is poorly understood. We sought to reveal early steps in BRCA2-associated carcinogenesis through anal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7aca1536bb1e9698d683f92a1ea1e17
https://doi.org/10.1101/729301
https://doi.org/10.1101/729301
Autor:
Mihriban, Karaayvaz-Yildirim, Rebecca E, Silberman, Adam, Langenbucher, Srinivas Vinod, Saladi, Kenneth N, Ross, Elena, Zarcaro, Andrea, Desmond, Murat, Yildirim, Varunika, Vivekanandan, Hiranmayi, Ravichandran, Ravindra, Mylavagnanam, Michelle C, Specht, Sridhar, Ramaswamy, Michael, Lawrence, Angelika, Amon, Leif W, Ellisen
Publikováno v:
Science Advances
Normal breast epithelia from BRCA2 mutation carriers display DNA damage and attenuated checkpoint responses.
Women harboring heterozygous germline mutations of BRCA2 have a 50 to 80% risk of developing breast cancer, yet the pathogenesis of thes
Women harboring heterozygous germline mutations of BRCA2 have a 50 to 80% risk of developing breast cancer, yet the pathogenesis of thes